tirzepatide/levocarnitine injection Tirzepatide Injection Troubling Findings in Study of

Key findings include: Unprecedented HbA1c reductions ranging from 1.9% to 2.6% across different trials and populations SURPASS-1 (monotherapy): Up to 92% of participants achieved HbA1c less than 7%, with 52% reaching normoglycemia (HbA1c less than 5.7%) SURPASS-2 (versus semaglutide 1 mg): GLP2 demonstrated superior HbA1c and weight reduction at all doses compared to the leading GLP-1 receptor agonist SURPASS-3 (versus insulin degludec): Superior glycemic control when added to metformin with or without SGLT2 inhibitors SURPASS-4 (versus insulin glargine): Improved outcomes in patients with elevated cardiovascular risk Across all SURPASS trials, GLP2 showed consistent efficacy with low rates of clinically significant hypoglycemia (blood glucose less than 54 mg/dL)

* Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S

If you have diabetes, check your blood or urine ketones when glucose readings are high or if you're experiencing symptoms of hyperglycemia

If you are interested in exploring oral semaglutide or other medically supervised weight loss options, book a consultation to receive a personalised treatment plan and ongoing support for safe, sustainable results

Get a FREE 15-minute Virtual Protocol Review + our Regenerative Treatment Newsletter